Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis

Show simple item record

dc.contributor.author Lemmer, Yolandy
dc.contributor.author Kalombo, Lonji
dc.contributor.author Pietersen, Ray-Dean
dc.contributor.author Jones, Arwyn T.
dc.contributor.author Semete-Makokotlela, Boitumelo
dc.contributor.author Van Wyngaardt, Sandra
dc.contributor.author Ramalapa, Bathabile
dc.contributor.author Stoltz, Anton C.
dc.contributor.author Baker, Bienyameen
dc.contributor.author Verschoor, Jan A.
dc.contributor.author Swai, Hulda
dc.contributor.author de Chastellier, Chantal
dc.date.accessioned 2019-10-18T06:22:47Z
dc.date.available 2019-10-18T06:22:47Z
dc.date.issued 2015-06-06
dc.identifier.uri http://dx.doi.org/10.1016/j.jconrel.2015.06.005
dc.identifier.uri http://dspace.nm-aist.ac.tz/handle/123456789/501
dc.description Research Article published by Elsevier en_US
dc.description.abstract The appearance of drug-resistant strains of Mycobacterium tuberculosis (Mtb) poses a great challenge to the development of novel treatment programmes to combat tuberculosis. Since innovative nanotechnologiesmight alleviate the limitations of current therapies, we have designed a new nanoformulation for use as an anti-TB drug delivery system. It consists of incorporating mycobacterial cellwallmycolic acids (MA) as targeting ligands into a drug-encapsulating Poly DL-lactic-co-glycolic acid polymer (PLGA), via a double emulsion solvent evaporation technique. Bonemarrow-derivedmousemacrophages, either uninfected or infectedwith differentmycobacterial strains (Mycobacterium avium, Mycobacterium bovis BCG or Mtb), were exposed to encapsulated isoniazid-PLGA nanoparticles (NPs) using MA as a targeting ligand. The fate of the NPs was monitored by electron microscopy. Our study showed that i) the inclusion of MA in the nanoformulations resulted in their expression on the outer surface and a significant increase in phagocytic uptake of the NPs; ii) nanoparticle-containing phagosomes were rapidly processed into phagolysosomes, whether MA had been included or not; and iii) nanoparticlecontaining phagolysosomes did not fuse with non-matured mycobacterium-containing phagosomes, but fusion events with mycobacterium-containing phagolysosomes were clearly observed. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.subject Tuberculosis en_US
dc.subject Mycolic acids en_US
dc.subject Nanodrug delivery en_US
dc.subject Electron microscopy en_US
dc.title Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis en_US
dc.type Article en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Our NM-AIST IR


My NM-AIST IR Account